Check for updates

Drug discovery with explainable artificial intelligence

José Jiménez-Luna [1,2], Francesca Grisoni [1,2] and Gisbert Schneider [1✉]

Deep learning bears promise for drug discovery, including advanced image analysis, prediction of molecular structure and function, and automated generation of innovative chemical entities with bespoke properties. Despite the growing number of successful prospective applications, the underlying mathematical models often remain elusive to interpretation by the human mind. There is a demand for 'explainable' deep learning methods to address the need for a new narrative of the machine language of the molecular sciences. This Review summarizes the most prominent algorithmic concepts of explainable artificial intelligence, and forecasts future opportunities, potential applications as well as several remaining challenges. We also hope it encourages additional efforts towards the development and acceptance of explainable artificial intelligence techniques.

Various concepts of 'artificial intelligence' (AI) have been successfully adopted for computer-assisted drug discovery in the past few years[1–3]. This advance is mostly owed to the ability of deep learning algorithms, that is, artificial neural networks with multiple processing layers, to model complex nonlinear input–output relationships, and perform pattern recognition and feature extraction from low-level data representations. Certain deep learning models have been shown to match or even exceed the performance of the familiar existing machine learning and quantitative structure–activity relationship (QSAR) methods for drug discovery[4–6]. Moreover, deep learning has boosted the potential and broadened the applicability of computer-assisted discovery, for example, in molecular design[7,8], chemical synthesis planning[9,10], protein structure prediction[11] and macromolecular target identification[12,13].

The ability to capture intricate nonlinear relationships between input data (for example, chemical structure representations) and the associated output (for example, assay readout) often comes at the price of limited comprehensibility of the resulting model. While there have been efforts to explain QSARs in terms of algorithmic insights and molecular descriptor analysis[14–19], deep neural network models notoriously elude immediate accessibility by the human mind[20]. In medicinal chemistry in particular, the availability of 'rules of thumb' correlating biological effects with physicochemical properties underscores the willingness, in certain situations, to sacrifice accuracy in favour of models that better fit human intuition[21–23]. Thus, blurring the lines between the 'two QSARs'[24] (that is, mechanistically interpretable versus highly accurate models) may be key to accelerated drug discovery with AI[25].

Automated analysis of medical and chemical knowledge to extract and represent features in a human-intelligible format dates back to the 1990s[26,27], but has been receiving increasing attention due to the re-emergence of neural networks in chemistry and healthcare. Given the current pace of AI in drug discovery and related fields, there will be an increased demand for methods that help us understand and interpret the underlying models. In an effort to mitigate the lack of interpretability of certain machine learning models, and to augment human reasoning and decision-making,[28] attention has been drawn to explainable AI (XAI) approaches[29,30].

Providing informative explanations alongside the mathematical models aims to (1) render the underlying decision-making process transparent ('understandable')[31], (2) avoid correct predictions for the wrong reasons (the so-called clever Hans effect)[32], (3) avert unfair biases or unethical discrimination[33] and (4) bridge the gap between the machine learning community and other scientific disciplines. In addition, effective XAI can help scientists navigate 'cognitive valleys'[28], allowing them to hone their knowledge and beliefs on the investigated process[34].

While the exact definition of XAI is still under debate[35], in the authors' opinion, several aspects of XAI are certainly desirable in drug design applications[29]:

- Transparency—knowing how the system reached a particular answer.
- Justification—elucidating why the answer provided by the model is acceptable.
- Informativeness—providing new information to human decision-makers.
- Uncertainty estimation—quantifying how reliable a prediction is.

In general, XAI-generated explanations can be categorized as global (that is, summarizing the relevance of input features in the model) or local (that is, based on individual predictions)[36]. Moreover, XAI can be dependent on the underlying model, or agnostic, which in turn affects the potential applicability of each method. In this framework, there is no one-fits-all XAI approach.

There are many domain-specific challenges for future AI-assisted drug discovery, such as the data representation fed to said approaches. In contrast to many other areas in which deep learning has been shown to excel, such as natural language processing and image recognition, there is no naturally applicable, complete, 'raw' molecular representation. After all, molecules—as scientists conceive them—are models themselves. Such an 'inductive' approach, which builds higher-order (for example, deep learning) models from lower-order ones (for example, molecular representations or descriptors based on observational statements) is therefore philosophically debatable[37]. The choice of the molecular 'representation model' becomes a limiting factor of the explainability and performance of the resulting AI model—as it determines of the content, type and interpretability of the chemical information retained (for example, pharmacophores, physicochemical properties, functional groups).

[1]RETHINK, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland. [2]These authors contributed equally: José Jiménez-Luna, Francesca Grisoni. ✉e-mail: gisbert@ethz.ch

Drug design is not straightforward. It distinguishes itself from clear-cut engineering by the presence of error, nonlinearity and seemingly random events[38]. We have to concede our incomplete understanding of molecular pathology and our inability to formulate infallible mathematical models of drug action and corresponding explanations. In this context, XAI bears the potential to augment human intuition and skills for designing novel bioactive compounds with desired properties.

Designing new drugs epitomizes in the question whether pharmacological activity ('function') can be deduced from the molecular structure, and which elements of such structure are relevant. Multi-objective design poses additional challenges and sometimes ill-posed problems, resulting in molecular structures that too often represent compromise solutions. The practical approach aims to limit the number of syntheses and assays needed to find and optimize new hit and lead compounds, especially when elaborate and expensive tests are performed. XAI-assisted drug design is expected to help overcome some of these issues, by allowing to take informed action while simultaneously considering medicinal chemistry knowledge, model logic and awareness on the system's limitations[39]. XAI will foster the collaboration between medicinal chemists, chemoinformaticians and data scientists[40,41]. In fact, XAI already enables the mechanistic interpretation of drug action[42,43], and contributes to drug safety enhancement, as well as organic synthesis planning[9,44]. If successful in the long run, XAI will provide fundamental support in the analysis and interpretation of increasingly more complex chemical data, as well as in the formulation of new pharmacological hypotheses, while avoiding human bias[45,46]. Pressing drug discovery challenges such as the coronavirus pandemic might boost the development of application-tailored XAI approaches, to promptly respond to specific scientific questions related to human biology and pathophysiology.

The field of XAI is still in its infancy but moving forward at a fast pace, and we expect an increase of its relevance in the years to come. In this Review, we aim to provide a comprehensive overview of recent XAI research, highlighting its benefits, limitations and future opportunities for drug discovery. In what follows, after providing an introduction to the most relevant XAI methods structured into conceptual categories, the existing and some of the potential applications to drug discovery are presented. Finally, we discuss the limitations of contemporary XAI and point to the potential methodological improvements needed to foster practical applicability of these techniques to pharmaceutical research.

A glossary of selected terms is provided in Box 1.

State of the art and future directions

This section aims to provide a concise overview of modern XAI approaches, and exemplify their use in computer vision, natural-language processing and discrete mathematics. We then highlight selected case studies in drug discovery and propose potential future areas and research directions of XAI in drug discovery. A summary of the methodologies and their goals, along with reported applications is provided in Table 1. In what follows, without loss of generality, f will denote a model (in most cases a neural network); $x \in \mathcal{X}$ will be used to denote the set of features describing a given instance, which are used by f to make a prediction $y \in \mathcal{Y}$.

Feature attribution methods. Given a regression or classification model $f : \boldsymbol{x} \in \mathbb{R}^K \to \mathbb{R}$ (where $\mathbb{R}$ refers to the set of real numbers, and K (as a superscript of $\mathbb{R}$) refers to a k-dimensional set of real numbers), a feature attribution method is a function $\mathcal{E} : \boldsymbol{x} \in \mathbb{R}^K \to \mathbb{R}^K$ that takes the model input and produces an output whose values denote the relevance of every input feature for the final prediction computed with f. Feature attribution methods can be grouped into the following three categories (Fig. 1).

Box 1 | Glossary of selected terms

Active learning. Field of machine learning in which an underlying model can query an oracle (for example, an expert or any other information source) in an active manner to label new data points with the goal of learning a task more efficiently.

Activity cliff. A small structural modification of a molecule that results in a marked change in its bioactivity.

Ensemble approach. Combination of the predictions of multiple base models with the goal to obtain a single one with improved overall performance metrics.

Cytochrome P450. Superfamily of structurally diverse metabolic enzymes, accounting for about 75% of the total drug metabolism in the human body.

Fragment-based virtual screening. Computational approach aimed to obtain promising hit or lead compounds based on the presence of specified molecular fragments (for example, molecular substructures known to possess or convey a certain desired biological activity).

Functional group. Part of a molecule that may be involved in characteristic chemical reactions or molecular interactions.

Gaussian process. Supervised, Bayesian-inspired machine learning model that naturally handles uncertainty estimation over its predictions. It does so by inducing a prior over functions with a covariance function that measures similarity among the inputs. Gaussian process models are often used for solving regression tasks.

Hit-to-lead optimization. Early stage of the drug discovery process in which the initial 'hits' (that is, molecules with a desired activity) undergo a filtering and optimization process to select the most promising ones ('leads').

Lead optimization. Process by which the potency, selectivity and pharmacokinetic parameters of a compound ('lead structure') are improved to obtain a drug candidate. This optimization usually involves several design–make–test cycles.

Metabolism. Biochemical reactions that transform and remove endogenous and exogenous compounds from an organism.

Molecular descriptor. Numerical representation of molecular properties and/or structural features, generated by predefined algorithmic rules.

Molecular graph. Mathematical representation of the molecular topology, with nodes and edges representing atoms and chemical bonds, respectively.

Pharmacophore. The set of molecular features that are necessary for the specific interaction of a ligand with a biological receptor.

SMILES. String-based representation of a two-dimensional molecular structure in terms of its atom types, bond types and molecular connectivity.

Structural alert. Functional group and/or molecular substructure empirically linked to adverse properties, for example, compound toxicity or unwanted reactivity.

QSAR model. 'Quantitative structure–activity relationship' approaches are methodologies for predicting the physicochemical or biological properties of chemicals as a function of their molecular descriptors.

Table 1 | Computational approaches towards explainable AI in drug discovery and related disciplines, categorized according to the respective methodological concept

Family	Aim	Methods	Reported applications in drug discovery
Feature attribution	Determine local feature importance towards a prediction	• Gradient based • Surrogate models • Perturbation based	Ligand pharmacophore identification[55,71,79,80], structural alerts for adverse effect[67], protein–ligand interaction profiling[72]
Instance based	Compute a subset of features that need to be present or absent to guarantee or change a prediction	• Anchors • Counterfactual instances • Contrastive explanations	Not reported
Graph convolution based	Interpret models within the message-passing framework	• Subgraph approaches • Attention based	Retrosynthesis elucidation[101], toxicophore and pharmacophore identification[41], ADMET[a][102,103] reactivity prediction[104]
Self-explaining	Develop models that are explainable by design	• Prototype based • Self-explaining neural networks • Concept learning • Natural language explanations	Not reported
Uncertainty estimation	Quantify the reliability of a prediction	• Ensemble based • Probabilistic • Other approaches	Reaction prediction[147], active learning[148], molecular activity prediction[168]

For each family of approaches, a brief description of its aim is provided, along with specific methods and reported applications in drug discovery. 'Not reported' refers to families of methods that, to the best of our knowledge, have not been yet applied in drug discovery. Potential applications of these are discussed in the main text. [a]ADMET: absorption, distribution, metabolism, excretion and toxicity.


Fig. 1 | Feature attribution methods. Given a neural network model f, which computes the prediction $y = f(x)$ for input sample x, a feature attribution method $\mathcal{E}$ outputs the relevance of every input feature of x for the prediction. There are three basic approaches to determine feature relevance: (1) gradient-based methods, computing the gradient of the network f with respect to the input x, (2) surrogate methods, which approximate f with a human-interpretable model g, and (3) perturbation-based methods, which modify the original input to measure the respective changes in the output.

- **Gradient-based feature attribution.** These approaches measure how much a change around a local neighbourhood of the input x corresponds to a change in the output $f(x)$. A common approach among deep-learning practitioners relies on the use of the derivative of the output of the neural network with respect to the input (that is, $\delta f/\delta x$) to determine feature importance[47,48]. Its popularity arises partially from the fact that this computation can be performed via back-propagation[49], the main way of computing partial first-order derivatives in neural network models. While the use of gradient-based feature attribution may seem straightforward, several methods relying on this principle have been shown to lead to only partial reconstruction of the original features[50], which is prone to misinterpretation.
- **Surrogate-model feature attribution.** Given a model f, these methods aim to develop a surrogate explanatory model g, which is constructed in such a way that: (1) g is interpretable and

(2) g approximates the original function f. A prominent example of this concept is the family of additive feature attribution methods, where the approximation is achieved through a linear combination of binary variables z_i:

$$g(z_i') = \phi_0 + \sum_{i=1}^{M} \phi_i z_i, \qquad (1)$$

where $z_i \in \{0, 1\}^M$, M is the number of original input features, $\phi_i \in \mathbb{R}$ are coefficients representing the importance assigned to each ith binary variable and ϕ_0 is an intercept. Several notable feature attribution methods belong to this family[51,52], such as local interpretable model-agnostic explanations (LIME)[53], Deep Learning Important FeaTures (DeepLIFT)[54], Shapley additive explanations (SHAP)[52] and layer-wise relevance propagation[55]. Both gradient-based methods and the additive subfamily of surrogate attribution methods provide local explanations (that is, each prediction needs to be examined individually), but they do not offer a general understanding of the underlying model f. Global surrogate explanation models aim to fill this gap by generically describing f via a decision tree or decision set[56] model. If such an approximation is precise enough, these aim to to mirror the computation logic of the original model. While early attempts limited f to the family of tree-based ensemble methods (for example, random forests[57]), more recent approaches are readily applicable to arbitrary deep learning models[58].

- **Perturbation-based methods** modify or remove parts of the input aiming to measure its corresponding change in the model output; this information is then used to assess the feature importance. Alongside the well-established step-wise approaches[59,60], methods such as feature masking[61], perturbation analysis[62], response randomization[63] and conditional multivariate models[64] belong to this category. While perturbation-based methods have the advantage of directly estimating feature importance, they are computationally slow when the number of input features increases[64], and the final result tends to be strongly influenced by the number of features that are perturbed altogether[65].

Feature attribution methods have been the most used XAI family of techniques for ligand- and structure-based drug discovery in the past few years. For instance, McCloskey et al.[66] employed

Box 2 | XAI applied to cytochrome P450-mediated metabolism

This worked example showcases XAI that provides a graphical explanation in terms of molecular motifs that are considered relevant by a neural network model predicting drug interaction with cytochrome P450 (3A4 isoform, CYP3A4). The integrated gradients feature attribution method[47] was combined with a graph convolutional neural network for predicting drug–CYP3A4 interaction. This network model was trained with a publicly available set of CYP3A4 substrates and inhibitors[169]. The figure shows the results obtained for two drugs that are metabolized predominantly by CYP3A4, namely the phosphodiesterase A inhibitor (antiplatelet agent) cilostazol and nifedipine, an L-type calcium channel blocker.

The structural features for CYP3A4–compound interaction suggested by the XAI method are highlighted in colour (left panel 'in silico': blue, positive contribution to interaction with CYP3A4; orange, negative contribution to interaction; spot size indicates the feature relevance of the respective atom). The main sites of metabolism (dashed circles) and the known metabolites[170–172] are shown in the right panel ('experimental'). Apparently, the XAI captured the chemical substructures involved in CYP3A4-mediated biotransformation and most of the known sites of metabolism. Additional generic features related to metabolism were identified, that is, (1) the tetrazole moiety and the secondary amino group in cilostazol, which are known to increase metabolic stability (left panel: orange, negative contribution to the CYP3A4–cilostazol interaction), and (2) metabolically labile groups, such as methyl and ester groups (left panel: blue, positive contribution to the CYP3A4–nifedipine interaction).

gradient-based attribution[47] to detect ligand pharmacophores relevant for binding. The study showed that, despite good performance of the models on held-out data, these still can learn spurious correlations[66]. Pope et al.[67] adapted gradient-based feature attribution[68,69] for the identification of relevant functional groups in adverse effect prediction[70]. Recently, SHAP[52] was used to interpret relevant features for compound potency and multitarget activity prediction[71]. Hochuli et al.[72] compared several feature attribution methodologies, showing how the visualization of attributions assists in the parsing and interpretation of protein-ligand scoring with three-dimensional convolutional neural networks[73,74].

It should be noted that the interpretability of feature attribution methods is limited by the original set of features (model input). Particularly in drug discovery, the interpretability is often hampered by the use of complex or 'opaque' input molecular descriptors[75]. When making use of feature attribution approaches, it is advisable to choose comprehensible molecular descriptors or representations for model construction (Box 2). Recently, architectures borrowed from the natural language processing field, such as long short-term memory networks[76] and transformers[77], have been used as feature attribution techniques to identify portions of simplified molecular input line entry systems (SMILES)[78] strings that are relevant for bioactivity or physicochemical properties[79,80]. These approaches constitute a first attempt to bridge the gap between the deep learning and medicinal chemistry communities, by relying on representations (atom and bond types, and molecular connectivity[78]) that bear direct chemical meaning and need no posterior descriptor-to-molecule decoding.

Instance-based approaches. Instance-based approaches compute a subset of relevant features (instances) that must be present to retain (or absent to change) the prediction of a given model (Fig. 2). An instance can be real (that is, drawn from the set of data) or generated for the purposes of the method. Instance-based approaches have been argued to provide 'natural' model interpretations for humans, because they resemble counterfactual reasoning

Fig. 2 | Instance-based model interpretation. Given a model *f*, input instance *x* and the respective predicted class *c*, so-called anchor algorithms identify a minimal subset of features of *x* that are sufficient to preserve the predicted class assignment *c*. Counterfactual search generates a new instance *x′* that lies close in feature space to *x* but is classified differently by the model, as belonging to class *c′*.

(that is, producing alternative sets of action to achieve a similar or different result)[81].

- Anchor algorithms[82] offer model-agnostic interpretable explanations of classifier models. They compute a subset of if-then rules based on one or more features that represent conditions to sufficiently guarantee a certain class prediction. In contrast to many other local explanation methods[53], anchors therefore explicitly model the 'coverage' of an explanation. Formally, an anchor *A* is defined as a set of rules such that, given a set of features *x* from a sample, they return $A(x) = 1$ if said rules are met, while guaranteeing the desired predicted class from *f* with a certain probability τ:

$$\mathbb{E}_{\mathcal{D}(z|A)}\left[\mathbb{1}_{f(x)=f(z)}\right] \geq \tau, \tag{2}$$

where $\mathcal{D}(z|A)$ is defined as the conditional distribution on samples where anchor *A* applies. This methodology has successfully been applied in several tasks such as image recognition, text classification and visual question answering[82].

- Counterfactual instance search. Given a classifier model *f* and an original data point *x*, counterfactual instance search[83] aims to find examples *x′* (1) that are as close to *x* as possible and (2) for which the classifier produces a different class label from the label assigned to *x*. In other words, a counterfactual describes small feature changes in sample *x* such that it is classified differently by *f*. The search for the set of instances *x′* may be cast into an optimization problem:

$$\min_{x'} \max_{\lambda}(f_t - p_t)^2 + \lambda L_1(x', x), \tag{3}$$

where f_t is the prediction of the model for the *t*th class, p_t is a user-defined target probability for the same class, L_1 is the Manhattan distance between the proposed *x′* and the original sample *x*, and λ is an optimizable parameter that controls the contribution of each term in the loss. The first term in this loss encourages the search towards points that change the prediction of the model, while the second ensures that both *x* and *x′* lie close to each other in their input manifold. While in the original paper this approach was shown to successfully obtain counterfactuals in several datasets, the results revealed a tendency to look artificial. A recent methodology[84] mitigates this problem by adding extra terms to the loss function with an autoencoder architecture, to better capture the original data distribution. Importantly, counterfactual instances can be evaluated using trust scores (cf. the section on uncertainty estimation). One can interpret a high trust score as the counterfactual being far from

the initially predicted class of *x* compared with the class assigned to the counterfactual *x′*.

- Contrastive explanation methods[85] provide instance-based interpretability of classifiers by generating 'pertinent positive' and 'pertinent negative' sets. This methodology is related to both anchors and counterfactual search approaches. Pertinent positives are defined as the smallest set of features that should be present in an instance for the model to predict a 'positive' result (similar to anchors). Conversely, pertinent negatives constitute the smallest set of features that should be absent for the model to be able to sufficiently differentiate from the other classes (similar to a counterfactual instance). This method generates explanations of the form 'An input *x* is classified as class *y* because a subset of features{$x_1, … x_k$} is present, and because a subset of features {$x_m, … x_p$} is absent'[81] (where *k*, *m* and *p* are arbitrary integer subscripts for *x* such that $k \leq m \leq p$). Contrastive explanation methods find such sets by solving two separate optimization problems, namely by (1) perturbing the original instance until it is predicted differently than its original class and (2) searching for critical features in the original input (that is, those features that guarantee a prediction with a high degree of certainty). The proposed approach uses an elastic net regularizer[86], and optionally a conditional autoencoder model[87] so that the found explanations are more likely to lie closer to the original data manifold.

In drug discovery, instance-based approaches can be valuable to enhance model transparency, by highlighting what molecular features need to be either present or absent to guarantee or change the model prediction. In addition, counterfactual reasoning further promotes informativeness, by exposing potential new information about both the model and the underlying training data for human decision-makers (for example, organic and medicinal chemists).

To the best of our knowledge, instance-based approaches have yet to be applied to drug discovery. In the authors' opinion, they bear promise in several areas of de novo molecular design, such as (1) activity cliff prediction, as they can help identify small structural variations in molecules that cause large bioactivity changes, (2) fragment-based virtual screening, by highlighting a minimal subset of atoms responsible for a given observed activity, and (3) hit-to-lead optimization, by helping identify the minimal set of structural changes required to improve one or more biological or physicochemical properties.

Graph-convolution-based methods. Molecular graphs are a natural mathematical representation of molecular topology, with nodes and edges representing atoms and chemical bonds, respectively (Fig. 3a)[75]. Their usage has been commonplace in chemoinformatics and mathematical chemistry since the late 1970s[88,89]. Thus, it does not come as a surprise in these fields to witness the increasing application of novel graph convolution neural networks[90], which formally fall under the umbrella of neural message-passing algorithms[91]. Generally speaking, convolution refers to a mathematical operation on two functions that produces a third function expressing how the shape of one is modified by the other. This concept is widely used in convolutional neural networks for image analysis. Graph convolutions naturally extend the convolution operation typically used in computer vision[92] or in natural language processing[93] applications to arbitrarily sized graphs. In the context of drug discovery, graph convolutions have been applied to molecular property prediction[94,95] and in generative models for de novo drug design[96].

Exploring the interpretability of models trained with graph convolution architectures is currently a particularly active research topic[97]. For the purpose of this review, XAI methods based on graph convolution are grouped into the following two categories.

Fig. 3 | Graph-based model interpretation. a, Kekulé structure of adrenaline and its respective molecular graph; atoms and bonds constitute nodes and edges, respectively. **b**, Given an input graph, approaches such as GNNExplainer[98] aim to identify a connected, compact subgraph, as well as node-level features that are relevant for a particular prediction y of a graph-neural network model f. **c**, Attention mechanisms can be used in conjunction with message-passing algorithms to learn coefficients $\alpha_{ij}^{(l)}$ for the lth layer, which assign 'importance' to the set of neighbours $\mathcal{N}(i)$ (for example, adjacent atoms) of a node i. These coefficients are an explicit component in the computation of new hidden-node representations $h_i^{(l+1)}$ (Eq. (5)) in attention-based graph convolutional architectures. Such learned attention coefficients can be then used to highlight the predictive relevance of certain edges and nodes.

- Subgraph identification approaches aim to identify one or more parts of a graph that are responsible for a given prediction (Fig. 3b). GNNExplainer[98] is a model-agnostic example of this category, and provides explanations for any graph-based machine learning task. Given an individual input graph, GNNExplainer identifies a connected subgraph structure, as well a set of node-level features that are relevant for a particular prediction. The method can also provide such explanations for a group of data points belonging to the same class. GNNExplainer is formulated as an optimization problem, where a mutual information objective between the prediction of a graph neural network and the distribution of feasible subgraphs is maximized. Mathematically, given a node v, the goal is to identify a subgraph $G_S \subseteq G$ with associated features $X_S = \{x_j | v_j \in G_S\}$ that are relevant in explaining a target prediction $\hat{y} \in Y$ via a mutual information measure MI:

$$\max_{G_S} \mathrm{MI}(Y, (G_S, X_S)) = \\ H(Y) - H(Y|G = G_S, X = X_S), \tag{4}$$

where H is an entropy term. In practice, however, this objective is not mathematically tractable, and several continuity and convexity assumptions have to be made.

- Attention-based approaches. The interpretation of graph-convolutional neural networks can benefit from attention mechanisms[99], which borrow from the natural language processing field, where their usage has become standard. The idea is to stack several message-passing layers to obtain hidden node-level representations, by first computing attention coefficients associated with each of the edges connected to the neighbours of a particular node in the graph (Fig. 3c). Mathematically, for a given node, an attention-based graph convolution operation obtains its updated hidden representation via a normalized sum of the node-level hidden features of the topological neighbours:

$$h_i^{(l+1)} = \sigma\left(\sum_{j \in \mathcal{N}(i)} \alpha_{ij}^l W^{(l)} h_j^{(l)}\right), \tag{5}$$

where $\mathcal{N}(i)$ is the set of topological neighbours of node i with a one-edge distance, α_{ij}^l are learned attention coefficients over those neighbours, σ is a nonlinear activation function and $W^{(l)}$ is a learnable feature matrix for layer l. The main difference between this approach and a standard graph convolution update is that, in the latter, attention coefficients are replaced by a fixed normalization constant $c_{ij} = \sqrt{|\mathcal{N}(i)|}\sqrt{|\mathcal{N}(j)|}$.

Methods based on graph convolution represent a powerful tool in drug discovery due to their immediate and natural connection with representations that are intuitive to chemists (that is, molecular graphs and subgraphs). In addition, the possibility to highlight atoms that are relevant towards a particular prediction, when combined with mechanistic knowledge, can improve both a model justification (that is, to elucidate if a provided answer is acceptable) and its informativeness on the underlying biological and chemical processes.

In particular, GNNExplainer was tested on a set of molecules labelled for their mutagenic effect on *Salmonella typhimurium*[100], and identified several known mutagenic functional groups (that is, certain aromatic and heteroaromatic rings and amino/nitro groups[100]) as relevant. A recent study[41] describes how the interpretation of filters in message-passing networks can lead to the identification of relevant pharmacophore- and toxicophore-like substructures, showing consistent findings with literature reports. Gradient-based feature attribution techniques, such as integrated gradients[47], were used in conjunction with graph convolutional networks to analyse retrosynthetic reaction predictions and highlight the atoms involved in each reaction step[101]. Attention-based graph convolutional neural networks have also been used for the prediction of solubility, polarity, synthetic accessibility and photovoltaic efficiency, among other properties[102,103], leading to the identification of relevant molecular substructures for the target properties. Finally, attention-based graph architectures have also been used in chemical reactivity prediction[104], pointing to structural motifs that are consistent with a chemist's intuition in the identification of suitable reaction partners and activating reagents.

Due to their intuitive connection with the two-dimensional representation of molecules, graph-convolution-based XAI bears the potential of being applicable to several other common modelling tasks in drug discovery. In the authors' opinion, XAI for graph convolution might be mostly beneficial to applications aimed at finding relevant molecular motifs, for example, structural alert identification and site of reactivity or metabolism prediction.

Self-explaining approaches. The XAI methods introduced so far produce a posteriori explanations of deep learning models. Although such post hoc interpretations have been shown to be useful, some argue that, ideally, XAI methods, should automatically offer human-interpretable explanation alongside their predictions[105]. Such approaches (herein referred to as 'self-explaining') would promote verification and error analysis, and be directly

linkable with domain knowledge[106]. While the term self-explaining has been coined to refer to a specific neural network architecture—self-explaining neural networks[106], described below—in this Review, the term is used in a broader sense, to identify methods that feature interpretability as a central part of their design. Self-explaining XAI approaches can be grouped into the following categories.

- Prototype-based reasoning refers to the task of forecasting future events (that is, novel samples) based on particularly informative known data points. Usually, this is done by identifying prototypes, that is, representative samples, which are adapted (or used directly) to make a prediction. These methods are motivated by the fact that predictions based on individual, previously seen examples mimic human decision-making[107]. The Bayesian case model[108] is a pre-deep-learning approach that constitutes a general framework for such prototype-based reasoning. A Bayesian case model learns to identify observations that best represent clusters in a dataset (that is, prototypes), along with a set of defining features for that cluster. Joint inference is performed on cluster labels, prototypes and extracted relevant features, thereby providing interpretability without sacrificing classification accuracy[108]. Recently, Li et al.[109] developed a neural network architecture composed of an autoencoder and a therein named 'prototype layer', whose units store a learnable weight vector representing an encoded training input. Distances between the encoded latent space of new inputs and the learned prototypes are then used as part of the prediction process. This approach was later expanded by Chen et al.[110] to convolutional neural networks for computer vision tasks.
- Self-explaining neural networks[106] aim to associate input or latent features with semantic concepts. They jointly learn a class prediction and generate explanations using a feature-to-concept mapping. Such a network model consists of (1) a subnetwork that maps raw inputs into a predefined set of explainable concepts, (2) a parameterizer that obtains coefficients for each individual explainable concept and (3) an aggregation function that combines the output of the previous two components to produce the final class prediction.
- Human-interpretable concept learning refers to the task of learning a class of concepts, that is, high-level combinations of knowledge elements[111], from data, aiming to achieve human-like generalization ability. The Bayesian programme learning approach[112] was proposed with the goal of learning visual concepts in computer vision tasks. Such concepts were represented as probabilistic programmes expressed as structured procedures in an abstract description language[113]. The model then composes more complex programmes using the elements of previously learned ones using a Bayesian criterion. This approach has been shown to reach human-like performance in one-shot learning tasks[114,115].
- Testing with concept activation vectors[116] computes the directional derivatives of the activations of a layer with respect to its input, towards the direction of a concept. Such derivatives quantify the degree to which the latter is relevant for a particular classification (for example, how important the concept 'stripes' is for the prediction of the class 'zebra'). It does so by considering the mathematical association between the internal state of a machine learning model—seen as a vector space E_m spanned by basis vectors e_m that correspond to neural activations—and human-interpretable activations residing in a different vector space E_h spanned by basis vectors e_h. A linear function is computed that translates between these vector spaces ($g: E_m \rightarrow E_h$). The association is achieved by defining a vector in the direction of the values of a concept's set of examples, and then training a linear classifier between those and random counterexamples, to finally take the vector orthogonal to the decision boundary.

- Natural language explanation generation. Deep networks can be designed to generate human-understandable explanations in a supervised manner[117]. In addition to minimizing the loss of the main modelling task, several approaches synthesize a sentence using natural language that explains the decision performed by the model, by simultaneously training generators on large datasets of human-written explanations. This approach has been applied to generate explanations that are both image and class relevant[118]. Another prominent application is visual question answering[119]. To obtain meaningful explanations, however, this approach requires a substantial amount of human-curated explanations for training, and might, thus, find limited applicability in drug discovery tasks.

Self-explaining methods possess several desirable aspects of XAI, but in particular we highlight their intrinsic transparency. By incorporating human-interpretable explanations at the core of their design, they avoid the common need of a post hoc interpretation methodology. The produced human-intelligible explanations might also provide natural insights on the justification of the provided predictions.

To the best of our knowledge, self-explaining deep learning has not been applied to chemistry or drug design yet. Including interpretability by design could help bridge the gap between machine representation and the human understanding of many types of problems in drug discovery. For instance, prototype-reasoning bears promise in the modelling of heterogeneous sets of chemicals with different modes of action, allowing the preservation of both mechanistic interpretability and predictive accuracy. Explanation generation (either concept or text based) is another potential solution to include human-like reasoning and domain knowledge in the model building task. In particular, explanation-generation approaches might be applicable to certain decision-making processes, such as the replacement of animal testing and in vitro to in vivo extrapolation, where human-understandable generated explanations constitute a crucial element.

Uncertainty estimation. Uncertainty estimation, that is, the quantification of errors in a prediction, constitutes another approach to model interpretation. While some machine learning algorithms, such as Gaussian processes[120], provide built-in uncertainty estimation, deep neural networks are known for being poor at quantifying uncertainty[121]. This is one of the reasons why several efforts have been devoted to specifically quantify uncertainty in neural network-based predictions. Uncertainty estimation methods can be grouped into the following categories.

- Ensemble approaches. Model ensembles improve the overall prediction quality and have become a standard for uncertainty estimates[122]. Deep ensemble averaging[123] is based on m identical neural network models that are trained on the same data and with a different initialization. The final prediction is obtained by aggregating the predictions of all models (for example, by averaging), while an uncertainty estimate can be obtained from the respective variance (Fig. 4a). Similarly, the sets of data on which these models are trained can be generated via bootstrap re-sampling[124]. A disadvantage of this approach is its computational demand, as the underlying methods build on m independently trained models. Snapshot ensembling[125] aims to overcome this limitation by periodically storing model states (that is, model parameters) along the training optimization path. These model 'snapshots' can be then used for constructing the ensemble.
- Probabilistic approaches aim to estimate the posterior probability of a certain model output or to perform post hoc calibration. Many of these methods treat neural networks as Bayesian models, by considering a prior distribution over its learnable

a

b

Fig. 4 | Uncertainty estimation. a, Ensemble-based methods aggregate the output of m identical, but differently initialized, models f_i. The final prediction is obtained by aggregating the predictions of all models (for example, as the average, $\bar{y}$), while an uncertainty estimate can be obtained from the respective predictive variance, for example, in the form of a standard deviation, s.d.(y). **b**, Bayesian probabilistic approaches consider a prior $p(\theta)$ over the learnable weights of a neural network model f_θ, and make use of approximate sampling approaches to learn a posterior distribution over both the weights $p(\theta|x)$ and the prediction $p_\theta(y|x)$. These distributions can be then sampled from to obtain uncertainty estimates over both the weights and the predictions.

weights, and then performing inference over their posterior distribution with various methods (Fig. 4b), for example, Markov chain Monte Carlo[126] or variational inference[127,128]. Gal et al.[129] suggested the usage of dropout regularization to perform approximate Bayesian inference, which was later extended[130] to compute epistemic (that is, caused by model mis-specification) and aleatoric uncertainty (inherent to the noise in the data). Similar approximations can also be made via batch normalization[131]. Mean variance estimation[132] considers a neural network designed to output both a mean and variance value, to then train the model using a negative Gaussian log-likelihood loss function. Another subcategory of approaches consider asymptotic approximations of a prediction by making Gaussian distributional assumptions of its error, such as the delta technique[133,134].

- Other approaches. The lower upper bound estimation (LUBE)[135] approach trains a neural network with two outputs, corresponding to the upper and lower bounds of the prediction. Instead of quantifying the error of single predictions, LUBE uses simulated annealing and optimizes the model coefficients to achieve (1) maximum coverage (probability that the real value of the ith sample will fall between the upper and the lower bound) of training measurements and (2) minimum prediction interval width. Ak et al. suggested to quantify the uncertainty in neural network models by directly modelling interval-valued data[136]. Trust scores[137] measure the agreement between a neural network and a k-nearest neighbour classifier that is trained on a filtered subset of the original data. The trust score considers both the distance between the instance of interest to the nearest class that is different from the original predicted one and its distance towards the predicted class. Union-based methods[138] first train a neural network model and then feed its embeddings to a second model that handles uncertainty, such as a Gaussian process or a random forest. Distance-based approaches[139] aim to estimate the prediction uncertainty of a new sample x' by measuring the distance to the closest sample in the training set, either using input features[140] or an embedding produced by the model[141].

Uncertainty is omnipresent in the natural sciences, and errors can arise from several sources. The methods described in this Review mainly address the epistemic error, that is, uncertainty in the model and hyperparameter choice. However, the aleatoric error, that is, the intrinsic randomness related to the inherent noise in experimental data, is independent from in silico modelling. It should be noted that this distinction of error types is usually not taken into consideration in practice because these two types of error are often inseparable. Accurately quantifying both types of error, however, could potentially increase the value of the information provided to medicinal chemists in active learning cycles, and facilitate decision-making during the compound optimization process[74].

Uncertainty estimation approaches have been successfully implemented in drug discovery applications[142], mostly in traditional QSAR modelling, either by the use of models that naturally handle uncertainty[143] or post hoc methods[144,145]. Attention has recently been drawn towards the development of uncertainty-aware deep learning applications in the field. Snapshot ensembling was applied to model 24 bioactivity datasets[146], showing that it performs on par with random forest and neural network ensembles, and also leads to narrower confidence intervals. Schwaller et al.[147] proposed a transformer model[77] for the task of forward chemical reaction prediction. This approach implements uncertainty estimation by computing the product of the probabilities of all predicted tokens in a SMILES sequence representing a molecule. Zhang et al.[148] have recently proposed a Bayesian treatment of a semi-supervised graph neural network for uncertainty-calibrated predictions of molecular properties, such as the melting point and aqueous solubility. Their results suggest that this approach can efficiently drive an active learning cycle, particularly in the low-data regime—by choosing those molecules with the largest estimated epistemic uncertainty. Importantly, a recent comparison of several uncertainty estimation methods for physicochemical property prediction showed that none of the methods systematically outperformed all others[149].

Often, uncertainty estimation methods are applied alongside models that are difficult to interpret, due to the utilized algorithms, molecular descriptors or a combination of both. Importantly, however, uncertainty estimation alone does not necessarily avert several known issues of deep learning, such as a model producing the right answer for unrelated or wrong reasons or highly reliable but wrong predictions[31,32]. Thus, enriching uncertainty estimation with concepts of transparency or justification remains a fundamental area of research to maximize the reliability and effectiveness of XAI in drug discovery.

Available software
Given the attention deep learning applications are currently receiving, several software tools have been developed to facilitate model interpretation. A prominent example is Captum[150], an extension of the PyTorch[151] deep learning and automatic differentiation package that provides support for most of the feature attribution techniques described in this work. Another popular package is Alibi[152], which provides instance-specific explanations for certain models trained with the scikit-learn[153] or TensorFlow[154] packages. Some of the explanation methods implemented include anchors, contrastive explanations and counterfactual instances.

Conclusions and outlook
In the context of drug discovery, full comprehensibility of deep learning models may be hard to achieve[38], although the provided predictions can still prove useful to the practitioner. When striving for interpretations that match the human intuition, it will be crucial to carefully devise a set of control experiments to validate the machine-driven hypotheses and increase their reliability and objectivity[40].

Current XAI also faces technical challenges, given the multiplicity of possible explanations and methods applicable to a given task[155]. Most approaches do not come as readily usable, 'out-of-the-box' solutions, but need to be tailored to each individual application. In addition, profound knowledge of the problem domain is crucial to identify which model decisions demand further explanations, which type of answers are meaningful to the user and which are instead trivial or expected[156]. For human decision-making, the explanations generated with XAI have to be non-trivial, non-artificial and sufficiently informative for the respective scientific community. At least for the time being, finding such solutions will require the collaborative effort of deep-learning experts, chemoinformaticians and data scientists, chemists, biologists and other domain experts, to ensure that XAI methods serve their intended purpose and deliver reliable answers.

It will be of particular importance to further explore the opportunities and limitations of the established chemical language for representing the decision space of these models. One step forward is to build on interpretable 'low level' molecular representations that have direct meaning for chemists and are suited for machine learning (for example, SMILES strings[157,158], amino acid sequences[159,160] and spatial three-dimensional voxelized representations[73,161]). Many recent studies rely on well-established molecular descriptors, such as hashed binary fingerprints[162,163] and topochemical and geometrical descriptors[164,165], which capture structural features defined a priori. Often, molecular descriptors, while being relevant for subsequent modelling, capture intricate chemical information. Consequently, when striving for XAI, there is an understandable tendency to employ molecular representations that can be more easily rationalized in terms of the known language of chemistry. Model interpretability depends on both the chosen molecular representation and the chosen machine learning approach[40]. With that in mind, the development of novel interpretable molecular representations for deep learning will constitute a critical area of research for the years to come, including the development of self-explaining approaches to overcome the hurdles of non-interpretable but information-rich descriptors, by providing human-like explanations alongside sufficiently accurate predictions.

Due to the current lack of methods comprising all of the outlined desirable features of XAI (transparency, justification, informativeness and uncertainty estimation), a major role in the short and mid term will be played by consensus (jury) approaches that combine the strengths of individual (X)AI approaches and increase model reliability. In the long run, jury XAI approaches—by relying on different algorithms and molecular representations—will constitute a way to provide multifaceted vantage points of the modelled biochemical process. Most of the deep learning models in drug discovery currently do not consider applicability domain restrictions[166,167], that is, the region of chemical space where statistical learning assumptions are met. These restrictions should, in the authors' opinion, be considered an integral element of XAI, as their assessment and a rigorous evaluation of model accuracy has proven to be more relevant for decision-making than the modelling approach itself[168]. Knowing when to apply which particular model will probably help address the problem of high confidence of deep learning models on wrong predictions[121] and avoid unnecessary extrapolations at the same time. Along those lines, in time- and cost-sensitive scenarios, such as drug discovery, deep learning practitioners have the responsibility to cautiously inspect and interpret the predictions derived from their modelling choices. Keeping in mind the current possibilities and limitations of XAI in drug discovery, it is reasonable to assume that the continued development of mixed approaches and alternative models that are more easily comprehensible and computationally affordable will not lose its importance.

At present, XAI in drug discovery lacks an open-community platform for sharing and improving software, model interpretations and the respective training data by synergistic efforts of researchers with different scientific backgrounds. Initiatives such as MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery, melloddy.eu) for decentralized, federated model development and secure data handling across pharmaceutical companies constitute a first step in the right direction. Such kinds of collaboration will hopefully foster the development, validation and acceptance of XAI and the associated explanations these tools provide.

References

1. Gawehn, E., Hiss, J. A. & Schneider, G. Deep learning in drug discovery. *Mol. Inform.* **35**, 3–14 (2016).
2. Zhang, L., Tan, J., Han, D. & Zhu, H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. *Drug Discov. Today* **22**, 1680–1685 (2017).
3. Muratov, E. N. et al. QSAR without borders. *Chem. Soc. Rev.* **49**, 3525–3564 (2020).
4. Lenselink, E. B. et al. Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set. *J. Cheminform.* **9**, 45 (2017).
5. Goh, G. B., Siegel, C., Vishnu, A., Hodas, N. O. & Baker, N. Chemception: a deep neural network with minimal chemistry knowledge matches the performance of expert-developed QSAR/QSPR models. Preprint at https://arxiv.org/abs/1706.06689 (2017).
6. Unterthiner, T. et al. Deep learning as an opportunity in virtual screening. In *Proc. Deep Learning Workshop at NIPS* **27**, 1–9 (NIPS, 2014).
7. Merk, D., Friedrich, L., Grisoni, F. & Schneider, G. De novo design of bioactive small molecules by artificial intelligence. *Mol. Inform.* **37**, 1700153 (2018).
8. Zhavoronkov, A. et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat. Biotechnol.* **37**, 1038–1040 (2019).
9. Schwaller, P., Gaudin, T., Lanyi, D., Bekas, C. & Laino, T. 'Found in translation': predicting outcomes of complex organic chemistry reactions using neural sequence-to-sequence models. *Chem. Sci.* **9**, 6091–6098 (2018).
10. Coley, C. W., Green, W. H. & Jensen, K. F. Machine learning in computer-aided synthesis planning. *Acc. Chem. Res.* **51**, 1281–1289 (2018).
11. Senior, A. W. et al. Improved protein structure prediction using potentials from deep learning. *Nature* **577**, 706–710 (2020).
12. Öztürk, H., Özgür, A. & Ozkirimli, E. DeepDTA: deep drug–target binding affinity prediction. *Bioinformatics* **34**, i821–i829 (2018).
13. Jimenez, J. et al. Pathwaymap: molecular pathway association with self-normalizing neural networks. *J. Chem. Inf. Model.* **59**, 1172–1181 (2018).
14. Marchese Robinson, R. L., Palczewska, A., Palczewski, J. & Kidley, N. Comparison of the predictive performance and interpretability of random forest and linear models on benchmark data sets. *J. Chem. Inf. Model.* **57**, 1773–1792 (2017).
15. Webb, S. J., Hanser, T., Howlin, B., Krause, P. & Vessey, J. D. Feature combination networks for the interpretation of statistical machine learning models: application to Ames mutagenicity. *J. Cheminform.* **6**, 8 (2014).
16. Grisoni, F., Consonni, V. & Ballabio, D. Machine learning consensus to predict the binding to the androgen receptor within the CoMPARA project. *J. Chem. Inf. Model.* **59**, 1839–1848 (2019).
17. Chen, Y., Stork, C., Hirte, S. & Kirchmair, J. NP-scout: machine learning approach for the quantification and visualization of the natural product-likeness of small molecules. *Biomolecules* **9**, 43 (2019).
18. Riniker, S. & Landrum, G. A. Similarity maps—a visualization strategy for molecular fingerprints and machine-learning methods. *J. Cheminform.* **5**, 43 (2013).
19. Marcou, G. et al. Interpretability of sar/qsar models of any complexity by atomic contributions. *Mol. Inform.* **31**, 639–642 (2012).
20. Rudin, C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. *Nat. Mach. Intell.* **1**, 206–215 (2019).
21. Gupta, M., Lee, H. J., Barden, C. J. & Weaver, D. F. The blood–brain barrier (BBB) score. *J. Med. Chem.* **62**, 9824–9836 (2019).
22. Rankovic, Z. CNS physicochemical property space shaped by a diverse set of molecules with experimentally determined exposure in the mouse brain: miniperspective. *J. Med. Chem.* **60**, 5943–5954 (2017).
23. Leeson, P. D. & Young, R. J. Molecular property design: does everyone get it? *ACS Med. Chem. Lett.* **6**, 722–725 (2015).
24. Fujita, T. & Winkler, D. A. Understanding the roles of the "two QSARs". *J. Chem. Inf. Model.* **56**, 269–274 (2016).
25. Schneider, P. et al. Rethinking drug design in the artificial intelligence era. *Nat. Rev. Drug Discov.* **19**, 353–364 (2020).

26. Hirst, J. D., King, R. D. & Sternberg, M. J. Quantitative structure–activity relationships by neural networks and inductive logic programming. I. The inhibition of dihydrofolate reductase by pyrimidines. *J. Comput. Aided Mol. Des.* **8**, 405–420 (1994).

27. Fiore, M., Sicurello, F. & Indorato, G. An integrated system to represent and manage medical knowledge. *Medinfo.* **8**, 931–933 (1995).

28. Goebel, R. et al. Explainable AI: the new 42? In *Machine Learning and Knowledge Extraction. CD-MAKE 2018. Lecture Notes in Computer Science* Vol. 11015 (eds Holzinger, A., Kieseberg, P., Tjoa, A. & Weippl, E) (Springer, 2018).

29. Lipton, Z. C. The mythos of model interpretability. *Queue* **16**, 31–57 (2018).

30. Murdoch, W. J., Singh, C., Kumbier, K., Abbasi-Asl, R. & Yu, B. Definitions, methods, and applications in interpretable machine learning. *Proc. Natl Acad. Sci. USA* **116**, 22071–22080 (2019).

31. Doshi-Velez, F. & Kim, B. Towards a rigorous science of interpretable machine learning. Preprint at https://arxiv.org/abs/1702.08608 (2017).

32. Lapuschkin, S. et al. Unmasking clever Hans predictors and assessing what machines really learn. *Nat. Commun.* **10**, 1096 (2019).

33. Miller, T. Explanation in artificial intelligence: insights from the social sciences. *Artif. Intell.* **267**, 1–38 (2019).

34. Chander, A., Srinivasan, R., Chelian, S., Wang, J. & Uchino, K. Working with beliefs: AI transparency in the enterprise. In *Joint Proceedings of the ACM IUI 2018 Workshops co-located with the 23rd ACM Conference on Intelligent User Interfaces* 2068 (eds Said, A. & Komatsu, T.) (CEUR-WS.org, 2018).

35. Guidotti, R. et al. A survey of methods for explaining black box models. *ACM Comput. Surv.* **51**, 93 (2018).

36. Lundberg, S. M. et al. From local explanations to global understanding with explainable AI for trees. *Nat. Mach. Intell.* **2**, 2522–5839 (2020).

37. Bendassolli, P. F. Theory building in qualitative research: reconsidering the problem of induction. *Forum Qual. Soc. Res.* **14**, 20 (2013).

38. Schneider, P. & Schneider, G. De novo design at the edge of chaos: .iniperspective. *J. Med. Chem.* **59**, 4077–4086 (2016).

39. Liao, Q. V., Gruen, D. & Miller, S. Questioning the AI: informing design practices for explainable AI user experiences. In *Proc. 2020 CHI Conference on Human Factors in Computing Systems, CHI '20* 1–15 (ACM, 2020).

40. Sheridan, R. P. Interpretation of QSAR models by coloring atoms according to changes in predicted activity: how robust is it? *J. Chem. Inf. Model.* **59**, 1324–1337 (2019).

41. Preuer, K., Klambauer, G., Rippmann, F., Hochreiter, S. & Unterthiner, T. in *Interpretable Deep Learning in Drug Discovery* (eds Samek W. et al.) 331–345 (Springer, 2019).

42. Xu, Y., Pei, J. & Lai, L. Deep learning based regression and multiclass models for acute oral toxicity prediction with automatic chemical feature extraction. *J. Chem. Inf. Model.* **57**, 2672–2685 (2017).

43. Ciallella, H. L. & Zhu, H. Advancing computational toxicology in the big data era by artificial intelligence: data-driven and mechanism-driven modeling for chemical toxicity. *Chem. Res. Toxicol.* **32**, 536–547 (2019).

44. Dey, S., Luo, H., Fokoue, A., Hu, J. & Zhang, P. Predicting adverse drug reactions through interpretable deep learning framework. *BMC Bioinform.* **19**, 476 (2018).

45. Kutchukian, P. S. et al. Inside the mind of a medicinal chemist: the role of human bias in compound prioritization during drug discovery. *PLoS ONE* **7**, e48476 (2012).

46. Boobier, S., Osbourn, A. & Mitchell, J. B. Can human experts predict solubility better than computers? *J. Cheminform.* **9**, 63 (2017).

47. Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. In *Proc. 34th International Conference on Machine Learning* Vol. 70, 3319–3328 (JMLR.org, 2017).

48. Smilkov, D., Thorat, N., Kim, B., Viégas, F. & Wattenberg, M. Smoothgrad: Removing noise by adding noise. Preprint at https://arxiv.org/abs/1706.03825 (2017).

49. Rumelhart, D. E., Hinton, G. E. & Williams, R. J. Learning representations by back-propagating errors. *Nature* **323**, 533–536 (1986).

50. Adebayo, J. et al. Sanity checks for saliency maps. *Adv. Neural Inf. Processing. Syst .* **31**, 9505–9515 (2018).

51. Lipovetsky, S. & Conklin, M. Analysis of regression in game theory approach. *Appl. Stoch. Models Bus. Ind.* **17**, 319–330 (2001).

52. Lundberg, S. M. & Lee, S.-I. A unified approach to interpreting model predictions. *Adv. Neural Inf. Process. Syst.* **30**, 4765–4774 (2017).

53. Ribeiro, M. T., Singh, S. & Guestrin, C. "Why should I trust you?" Explaining the predictions of any classifier. In *Proc. 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* 1135–1144 (ACM, 2016).

54. Shrikumar, A., Greenside, P. & Kundaje, A. Learning important features through propagating activation differences. In *Proc. 34th International Conference on Machine Learning* Vol. 70, 3145–3153 (JMLR.org, 2017).

55. Bach, S. et al. On pixel-wise explanations for non-linear classifier decisions by layer-wise relevance propagation. *PLoS ONE* **10**, 1–46 (2015).

56. Lakkaraju, H., Kamar, E., Caruana, R. & Leskovec, J. Interpretable & explorable approximations of black box models. Preprint at https://arxiv.org/abs/1707.01154 (2017).

57. Deng, H. Interpreting tree ensembles with intrees. *Int. J. Data Sci. Anal.* **7**, 277–287 (2019).

58. Bastani, O., Kim, C. & Bastani, H. Interpreting blackbox models via model extraction. Preprint at https://arxiv.org/abs/1705.08504 (2017).

59. Maier, H. R. & Dandy, G. C. The use of artificial neural networks for the prediction of water quality parameters. *Water Resour. Res.* **32**, 1013–1022 (1996).

60. Balls, G., Palmer-Brown, D. & Sanders, G. Investigating microclimatic influences on ozone injury in clover (*Trifolium subterraneum*) using artificial neural networks. *New Phytol.* **132**, 271–280 (1996).

61. Štrumbelj, E., Kononenko, I. & Šikonja, M. R. Explaining instance classifications with interactions of subsets of feature values. *Data Knowl. Eng.* **68**, 886–904 (2009).

62. Fong, R. C. & Vedaldi, A. Interpretable explanations of black boxes by meaningful perturbation. In *Proc. IEEE International Conference on Computer Vision* 3429–3437 (IEEE, 2017).

63. Olden, J. D. & Jackson, D. A. Illuminating the "black box": a randomization approach for understanding variable contributions in artificial neural networks. *Ecol. Model.* **154**, 135–150 (2002).

64. Zintgraf, L. M., Cohen, T. S., Adel, T. & Welling, M. Visualizing deep neural network decisions: prediction difference analysis. Preprint at https://arxiv.org/abs/1702.04595 (2017).

65. Ancona, M., Ceolini, E., Öztireli, C. & Gross, M. Towards better understanding of gradient-based attribution methods for deep neural networks. Preprint at https://arxiv.org/abs/1711.06104 (2017).

66. McCloskey, K., Taly, A., Monti, F., Brenner, M. P. & Colwell, L. J. Using attribution to decode binding mechanism in neural network models for chemistry. *Proc. Natl Acad. Sci. USA* **116**, 11624–11629 (2019).

67. Pope, P. E., Kolouri, S., Rostami, M., Martin, C. E. & Hoffmann, H. Explainability methods for graph convolutional neural networks. In *Proc. IEEE Conference on Computer Vision and Pattern Recognition* 10772–10781 (IEEE, 2019).

68. Selvaraju, R. R. et al. Grad-cam: visual explanations from deep networks via gradient-based localization. In *Pro. IEEE International Conference on Computer Vision* 618–626 (IEEE, 2017).

69. Zhang, J. et al. Top-down neural attention by excitation backprop. *Int. J. Comput. Vis.* **126**, 1084–1102 (2018).

70. Tice, R. R., Austin, C. P., Kavlock, R. J. & Bucher, J. R. Improving the human hazard characterization of chemicals: a Tox21 update. *Environ. Health Perspect.* **121**, 756–765 (2013).

71. Rodríguez-Pérez, R. & Bajorath, J. Interpretation of compound activity predictions from complex machine learning models using local approximations and Shapley values. *J. Med. Chem.* **63**, 8761–8777 (2019).

72. Hochuli, J., Helbling, A., Skaist, T., Ragoza, M. & Koes, D. R. Visualizing convolutional neural network protein-ligand scoring. *J. Mol. Graph. Model.* **84**, 96–108 (2018).

73. Jiménez-Luna, J., Skalic, M., Martinez-Rosell, G. & De Fabritiis, G. KDEEP: protein–ligand absolute binding affinity prediction via 3D-convolutional neural networks. *J. Chem. Inf. Model.* **58**, 287–296 (2018).

74. Jiménez-Luna, J. et al. DeltaDelta neural networks for lead optimization of small molecule potency. *Chem. Sci.* **10**, 10911–10918 (2019).

75. Todeschini, R. & Consonni, V. in *Molecular Descriptors for Chemoinformatics: Volume I: Alphabetical Listing/Volume II: Appendices, References* Vol. 41 (eds. Mannhold, R. et al.) 1–967 (Wiley, 2009).

76. Hochreiter, S. & Schmidhuber, J. Long short-term memory. *Neural Comput.* **9**, 1735–1780 (1997).

77. Vaswani, A. et al. Attention is all you need. *Adv. Neural Inf. Process. Syst .* **30**, 5998–6008 (2017).

78. Weininger, D. Smiles, a chemical language and information system. 1. Introduction to methodology and encoding rules. *J. Chem. Inf. Comput. Sci.* **28**, 31–36 (1988).

79. Grisoni, F. & Schneider, G. De novo molecular design with generative long short-term memory. *CHIMIA Int. J. Chem.* **73**, 1006–1011 (2019).

80. Karpov, P., Godin, G. & Tetko, I. V. Transformer-CNN: Swiss knife for QSAR modeling and interpretation. *J. Cheminform.* **12**, 17 (2020).

81. Doshi-Velez, F. et al. Accountability of AI under the law: the role of explanation. Preprint at https://arxiv.org/abs/1711.01134 (2017).

82. Ribeiro, M. T., Singh, S. & Guestrin, C. Anchors: high-precision model-agnostic explanations. In *Thirty-Second AAAI Conference on Artificial Intelligence* 1527–1535 (AAAI, 2018).

83. Wachter, S., Mittelstadt, B. & Russell, C. Counterfactual explanations without opening the black box: automated decisions and the GDPR. *Harv. J. Law Technol.* **31**, 841–888 (2017).

84. Van Looveren, A. & Klaise, J. Interpretable counterfactual explanations guided by prototypes. Preprint at https://arxiv.org/abs/1907.02584 (2019).

85. Dhurandhar, A. et al. Explanations based on the missing: towards contrastive explanations with pertinent negatives. *Adv. Neural Inf. Process. Syst.* **31**, 592–603 (2018).

86. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. *J. R. Stat. Soc. Ser. B* **67**, 301–320 (2005).

87. Mousavi, A., Dasarathy, G. & Baraniuk, R. G. Deepcodec: adaptive sensing and recovery via deep convolutional neural networks. Preprint at https://arxiv.org/abs/1707.03386 (2017).

88. Randić, M., Brissey, G. M., Spencer, R. B. & Wilkins, C. L. Search for all self-avoiding paths for molecular graphs. *Comput. Chem.* **3**, 5–13 (1979).

89. Bonchev, D. & Trinajstić, N. Information theory, distance matrix, and molecular branching. *J. Chem. Phys.* **67**, 4517–4533 (1977).

90. Duvenaud, D. K. et al. Convolutional networks on graphs for learning molecular fingerprints. *Adv. Neural Inf. Process. Syst.* **28**, 2224–2232 (2015).

91. Gilmer, J., Schoenholz, S. S., Riley, P. F., Vinyals, O. & Dahl, G. E. Neural message passing for quantum chemistry. In *Proc. 34th International Conference on Machine Learning* Vol. 70, 1263–1272 (JMLR.org, 2017).

92. Krizhevsky, A., Sutskever, I. & Hinton, G. E. ImageNet classification with deep convolutional neural networks. *Adv. Neural Inf. Process. Syst.* **25**, 1097–1105 (2012).

93. Kim, Y. Convolutional neural networks for sentence classification. Preprint at https://arxiv.org/abs/1408.5882 (2014).

94. Kearnes, S., McCloskey, K., Berndl, M., Pande, V. & Riley, P. Molecular graph convolutions: moving beyond fingerprints. *J. Comput. Aided Mol. Des.* **30**, 595–608 (2016).

95. Wu, Z. et al. Moleculenet: a benchmark for molecular machine learning. *Chem. Sci.* **9**, 513–530 (2018).

96. Jin, W., Barzilay, R. & Jaakkola, T. Junction tree variational autoencoder for molecular graph generation. Preprint at https://arxiv.org/abs/1802.04364 (2018).

97. Baldassarre, F. & Azizpour, H. Explainability techniques for graph convolutional networks. In *International Conference on Machine Learning (ICML) Workshops, 2019 Workshop on Learning and Reasoning with Graph-Structured Representations* (ICML, 2019).

98. Ying, Z., Bourgeois, D., You, J., Zitnik, M. & Leskovec, J. GNNExplainer: generating explanations for graph neural networks. *Adv. Neural Inf. Process. Syst.* **32**, 9240–9251 (2019).

99. Veličković, P. et al. Graph attention networks. Preprint at https://arxiv.org/abs/1710.10903 (2017).

100. Debnath, A. K., Lopez de Compadre, R. L., Debnath, G., Shusterman, A. J. & Hansch, C. Structure–activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity. *J. Med. Chem.* **34**, 786–797 (1991).

101. Ishida, S., Terayama, K., Kojima, R., Takasu, K. & Okuno, Y. Prediction and interpretable visualization of retrosynthetic reactions using graph convolutional networks. *J. Chem. Inf. Model.* **59**, 5026–5033 (2019).

102. Shang, C. et al. Edge attention-based multi-relational graph convolutional networks. Preprint at https://arxiv.org/abs/1802.04944 (2018).

103. Ryu, S., Lim, J., Hong, S. H. & Kim, W. Y. Deeply learning molecular structure–property relationships using attention-and gate-augmented graph convolutional network. Preprint at https://arxiv.org/abs/1805.10988 (2018).

104. Coley, C. W. et al. A graph-convolutional neural network model for the prediction of chemical reactivity. *Chem. Sci.* **10**, 370–377 (2019).

105. Laugel, T., Lesot, M.-J., Marsala, C., Renard, X. & Detynieki, M. The dangers of post-hoc interpretability: unjustified counterfactual explanations. In *Proceedings of the 28th International Joint Conference on Artificial Intelligence* 2801–2807 (AAAI, 2019)

106. Melis, D. A. & Jaakkola, T. Towards robust interpretability with self-explaining neural networks. *Adv. Neural Inf. Process. Syst.* **31**, 7775–7784 (2018).

107. Leake, D. B. in *Case-based Reasoning: Experiences, Lessons and Future Directions*, ch. 2 (ed. Leake, D. B.) (MIT Press, 1996).

108. Kim, B., Rudin, C. & Shah, J. A. The Bayesian case model: a generative approach for case-based reasoning and prototype classification. *Adv. Neural Inf. Process. Syst.* **27**, 1952–1960 (2014).

109. Li, O., Liu, H., Chen, C. & Rudin, C. Deep learning for case-based reasoning through prototypes: a neural network that explains its predictions. In *Thirty-Second AAAI Conference on Artificial Intelligence* 3530–3538 (AAAI, 2018).

110. Chen, C. et al. This looks like that: deep learning for interpretable image recognition. *Adv. Neural Inf. Process. Syst.* **32**, 8928–8939 (2019).

111. Goodman, N. D., Tenenbaum, J. B. & Gerstenberg, T. *Concepts in a Probabilistic Language of Thought* Technical Report (Center for Brains, Minds and Machines, 2014).

112. Lake, B. M., Salakhutdinov, R. & Tenenbaum, J. B. Human-level concept learning through probabilistic program induction. *Science* **350**, 1332–1338 (2015).

113. Ghahramani, Z. Probabilistic machine learning and artificial intelligence. *Nature* **521**, 452–459 (2015).

114. Vinyals, O., Blundell, C., Lillicrap, T., Kavukcuoglu, K. & Wierstra, D. Matching networks for one shot learning. *Adv. Neural Inf. Process. Syst.* **29**, 3630–3638 (2016).

115. Altae-Tran, H., Ramsundar, B., Pappu, A. S. & Pande, V. Low-data drug discovery with one-shot learning. *ACS Cent. Sci.* **3**, 283–293 (2017).

116. Kim, B., Wattenberg, M., Gilmer, J., Cai, C., Wexler, J., & Viegas, F. Interpretability beyond feature attribution: Quantitative testing with concept activation vectors (TCAV). In *International Conference on Machine Learning* 2668–2677 (2018).

117. Gilpin, L. H. et al. Explaining explanations: an overview of interpretability of machine learning. In *2018 IEEE 5th International Conference on Data Science and Advanced Analytics (DSAA)* 80–89 (IEEE, 2018).

118. Hendricks, L. A. et al. Generating visual explanations. *Computer Vision – ECCV 2016. ECCV 2016. Lecture Notes in Computer Science* Vol. 9908 (eds Leibe, B., Matas, J., Sebe, N. & Welling, M.) (Springer, 2016).

119. Antol, S. et al. VQA: visual question answering. In *Proc. IEEE International Conference on Computer Vision* 2425–2433 (IEEE, 2015).

120. Rasmussen, C. E. Gaussian processes in machine learning. In *Advanced Lectures on Machine Learning. Lecture Notes in Computer Science* Vol. 3176 (Springer, 2004).

121. Nguyen, A., Yosinski, J. & Clune, J. Deep neural networks are easily fooled: high confidence predictions for unrecognizable images. In *Proc. IEEE Conference on Computer Vision and Pattern Recognition* 427–436 (IEEE, 2015).

122. Hansen, L. K. & Salamon, P. Neural network ensembles. *IEEE Trans. Pattern Anal. Mach. Intell.* **12**, 993–1001 (1990).

123. Lakshminarayanan, B., Pritzel, A. & Blundell, C. Simple and scalable predictive uncertainty estimation using deep ensembles. *Adv. Neural Inf. Process. Syst.* **30**, 6402–6413 (2017).

124. Freedman, D. A. Bootstrapping regression models. *Ann. Stat.* **9**, 1218–1228 (1981).

125. Huang, G. et al. Snapshot ensembles: train one, get *m* for free. Preprint at https://arxiv.org/abs/1704.00109 (2017).

126. Zhang, R., Li, C., Zhang, J., Chen, C. & Wilson, A. G. Cyclical stochastic gradient MCMC for Bayesian deep learning. Preprint at https://arxiv.org/abs/1902.03932 (2019).

127. Graves, A. Practical variational inference for neural networks. *Adv. Neural Inf. Process. Syst.* **24**, 2348–2356 (2011).

128. Sun, S., Zhang, G., Shi, J. & Grosse, R. Functional variational bayesian neural networks. Preprint at https://arxiv.org/abs/1903.05779 (2019).

129. Gal, Y. & Ghahramani, Z. Dropout as a bayesian approximation: representing model uncertainty in deep learning. In *International Conference on Machine Learning* 1050–1059 (JMLR, 2016).

130. Kendall, A. & Gal, Y. What uncertainties do we need in bayesian deep learning for computer vision? *Adv. Neural Inf. Process. Syst.* **30**, 5574–5584 (2017).

131. Teye, M., Azizpour, H., & Smith, K. Bayesian uncertainty estimation for batch normalized deep networks. In *International Conference on Machine Learning* 4907–4916 (2018).

132. Nix, D. A. & Weigend, A. S. Estimating the mean and variance of the target probability distribution. In *Proc. 1994 IEEE International Conference on Neural Networks (ICNN'94)* Vol. 1, 55–60 (IEEE, 1994).

133. Chryssolouris, G., Lee, M. & Ramsey, A. Confidence interval prediction for neural network models. *IEEE Trans. Neural Netw.* **7**, 229–232 (1996).

134. Hwang, J. G. & Ding, A. A. Prediction intervals for artificial neural networks. *J. Am. Stat. Assoc.* **92**, 748–757 (1997).

135. Khosravi, A., Nahavandi, S., Creighton, D. & Atiya, A. F. Lower upper bound estimation method for construction of neural network-based prediction intervals. *IEEE Trans. Neural Netw.* **22**, 337–346 (2010).

136. Ak, R., Vitelli, V. & Zio, E. An interval-valued neural network approach for uncertainty quantification in short-term wind speed prediction. *IEEE Trans. Neural Netw. Learn. Syst.* **26**, 2787–2800 (2015).

137. Jiang, H., Kim, B., Guan, M. & Gupta, M. To trust or not to trust a classifier. *Adv. Neural Inf. Process. Syst.* **31**, 5541–5552 (2018).

138. Huang, W., Zhao, D., Sun, F., Liu, H. & Chang, E. Scalable Gaussian process regression using deep neural networks. In *Twenty-Fourth International Joint Conference on Artificial Intelligence* 3576–3582 (AAAI, 2015).

139. Sheridan, R. P., Feuston, B. P., Maiorov, V. N. & Kearsley, S. K. Similarity to molecules in the training set is a good discriminator for prediction accuracy in QSAR. *J. Chem. Inf. Comput. Sci.* **44**, 1912–1928 (2004).

140. Liu, R. & Wallqvist, A. Molecular similarity-based domain applicability metric efficiently identifies out-of-domain compounds. *J. Chem. Inf. Model.* **59**, 181–189 (2018).

141. Janet, J. P., Duan, C., Yang, T., Nandy, A. & Kulik, H. J. A quantitative uncertainty metric controls error in neural network-driven chemical discovery. *Chemi. Sci.* **10**, 7913–7922 (2019).

142. Scalia, G., Grambow, C. A., Pernici, B., Li, Y.-P. & Green, W. H. Evaluating scalable uncertainty estimation methods for deep learning-based molecular property prediction. *J. Chem. Inf. Model.* **60**, 2697–2717 (2020).

143. Obrezanova, O., Csányi, G., Gola, J. M. & Segall, M. D. Gaussian processes: a method for automatic QSAR modeling of ADME properties. *J. Chem. Inf. Model.* **47**, 1847–1857 (2007).

144. Schroeter, T. S. et al. Estimating the domain of applicability for machine learning QSAR models: a study on aqueous solubility of drug discovery molecules. *J. Comput. Aided Mol. Des.* **21**, 485–498 (2007).

145. Bosc, N. et al. Large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery. *J. Cheminform.* **11**, 4 (2019).

146. Cortés-Ciriano, I. & Bender, A. Deep confidence: a computationally efficient framework for calculating reliable prediction errors for deep neural networks. *J. Chem. Inf. Model.* **59**, 1269–1281 (2018).

147. Schwaller, P. et al. Molecular transformer: a model for uncertainty-calibrated chemical reaction prediction. *ACS Cent. Sci.* **5**, 1572–1583 (2019).

148. Zhang, Y. & Lee, A. A. Bayesian semi-supervised learning for uncertainty-calibrated prediction of molecular properties and active learning. *Chem. Sci.* **10**, 8154–8163 (2019).

149. Hirschfeld, L., Swanson, K., Yang, K., Barzilay, R. & Coley, C. W. Uncertainty quantification using neural networks for molecular property prediction. Preprint at https://arxiv.org/abs/2005.10036 (2020).

150. Kokhlikyan, N. et al. PyTorch Captum. *GitHub* https://github.com/pytorch/captum (2019).

151. Paszke, A. et al. PyTorch: an imperative style, high-performance deep learning library. *Adv. Neural Inf. Process. Syst.* **32**, 8026–8037 (2019).

152. Klaise, J., Van Looveren, A., Vacanti, G. & Coca, A. Alibi: algorithms for monitoring and explaining machine learning models. *GitHub* https://github.com/SeldonIO/alibi (2020).

153. Pedregosa, F. et al. Scikit-learn: machine learning in Python. *J. Mach. Learn. Res.* **12**, 2825–2830 (2011).

154. Abadi, M. et al. TensorFlow: a system for large-scale machine learning. In *12th USENIX Symposium on Operating Systems Design and Implementation (OSDI 16)* 265–283 (USENIX Association, 2016).

155. Lipton, Z. C. The doctor just won't accept that! Preprint at https://arxiv.org/abs/1711.08037 (2017).

156. Goodman, B. & Flaxman, S. European Union regulations on algorithmic decision-making and a 'right to explanation'. *AI Mag.* **38**, 50–57 (2017).

157. Ikebata, H., Hongo, K., Isomura, T., Maezono, R. & Yoshida, R. Bayesian molecular design with a chemical language model. *J. Comput. Aided Mol. Des.* **31**, 379–391 (2017).

158. Segler, M. H., Kogej, T., Tyrchan, C. & Waller, M. P. Generating focused molecule libraries for drug discovery with recurrent neural networks. *ACS Cent. Sci.* **4**, 120–131 (2018).

159. Nagarajan, D. et al. Computational antimicrobial peptide design and evaluation against multidrug-resistant clinical isolates of bacteria. *J. Biol. Chem.* **293**, 3492–3509 (2018).

160. Müller, A. T., Hiss, J. A. & Schneider, G. Recurrent neural network model for constructive peptide design. *J. Chem. Inf. Model.* **58**, 472–479 (2018).

161. Jiménez-Luna, J., Cuzzolin, A., Bolcato, G., Sturlese, M. & Moro, S. A deep-learning approach toward rational molecular docking protocol selection. *Molecules* **25**, 2487 (2020).

162. Rogers, D. & Hahn, M. Extended-connectivity fingerprints. *J. Chem. Inf. Model.* **50**, 742–754 (2010).

163. Awale, M. & Reymond, J.-L. Atom pair 2D-fingerprints perceive 3D-molecular shape and pharmacophores for very fast virtual screening of ZINC and GDB-17. *J. Chem. Inf. Model.* **54**, 1892–1907 (2014).

164. Todeschini, R. & Consonni, V. New local vertex invariants and molecular descriptors based on functions of the vertex degrees. *MATCH Commun. Math. Comput. Chem.* **64**, 359–372 (2010).

165. Katritzky, A. R. & Gordeeva, E. V. Traditional topological indexes vs electronic, geometrical, and combined molecular descriptors in QSAR/QSPR research. *J. Chem. Inf. Comput. Sci.* **33**, 835–857 (1993).

166. Sahigara, F. et al. Comparison of different approaches to define the applicability domain of qsar models. *Molecules* **17**, 4791–4810 (2012).

167. Mathea, M., Klingspohn, W. & Baumann, K. Chemoinformatic classification methods and their applicability domain. *Mol. Inform.* **35**, 160–180 (2016).

168. Liu, R., Wang, H., Glover, K. P., Feasel, M. G. & Wallqvist, A. Dissecting machine-learning prediction of molecular activity: is an applicability domain needed for quantitative structure–activity relationship models based on deep neural networks? *J. Chem. Inf. Model.* **59**, 117–126 (2019).

169. Nembri, S., Grisoni, F., Consonni, V. & Todeschini, R. In silico prediction of cytochrome P450-drug interaction: QSARs for CYP3A4 and CYP2C9. *Int. J. Mol. Sci.* **17**, 914 (2016).

170. Waller, D., Renwick, A., Gruchy, B. & George, C. The first pass metabolism of nifedipine in man. *Br. J. Clin. Pharmacol.* **18**, 951–954 (1984).

171. Hiratsuka, M. et al. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. *Drug Metab. Dispos.* **35**, 1730–1732 (2007).

172. Raemsch, K. D. & Sommer, J. Pharmacokinetics and metabolism of nifedipine. *Hypertension* **5**, II18 (1983).

Acknowledgements

Author contributions

All authors contributed equally to this manuscript.

Competing interests

G.S. declares a potential financial conflict of interest in his role as a co-founder of inSili.com GmbH, Zurich, and consultant to the pharmaceutical industry.

Additional information

Correspondence should be addressed to G.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.